Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Poziotinib’s Shift Of Focus To HER2 May Increase Approval Chances

Potential First-Line Therapy

Executive Summary

Encouraging new data for Spectrum/Hanmi’s poziotinib presented at ESMO may increase the chances of approval for the pan-HER inhibitor as a possible first-line therapy for NSCLC with the HER2 exon 20 insertion mutation, although the patient population is limited.

You may also be interested in...



Hanmi CEO On Success And Failure Of License Deals

The CEO of South Korea's Hanmi Pharm shares experiences around licensing deals and turning around returned assets, identifying "great opportunities" in the near term for the country's pharma and biotech sectors as global partners continue to hunt for novel products and technologies.

Turnaround For Spectrum’s Poziotinib As Phase II Cohort 2 Meets Endpoint

Spectrum is set to discuss NDA submission plans with the US FDA after unveiling positive top line results from Cohort 2 of the Phase II ZENITH20 study with poziotinib, in pretreated NSCLC patients with HER2 exon 20 insertion mutations. The drug, licensed from Hanmi, failed in the Cohort 1 part of the trial earlier this year.

EuBiologics On COVID-19 Vaccine And Fulfilling Public Health Mission

EuBiologics CEO Yeong Ok Baik sat down with Scrip at CPhI Korea to talk about why he wants to develop vaccines for global public health needs and what plans are in store for its late-stage recombinant protein candidate for COVID-19.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145138

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel